Literature DB >> 21976764

Epidemiology of invasive Streptococcus pyogenes infections in France in 2007.

A Lepoutre1, A Doloy, P Bidet, A Leblond, A Perrocheau, E Bingen, P Trieu-Cuot, A Bouvet, C Poyart, D Lévy-Bruhl.   

Abstract

Invasive group A streptococcal (GAS) infections cause significant morbidity and mortality. A national survey was initiated to assess the burden of invasive GAS infections in France, describe their clinical characteristics, and assess the molecular characteristics of GAS strains responsible for these infections. The survey was conducted in 194 hospitals, accounting for 51% of acute care hospital admissions in France. Clinical data, predisposing factors, and demographic data were obtained, and all GAS isolates were emm sequence typed. We identified 664 cases of invasive GAS infections, with an annual incidence of 3.1 per 100,000 population. The case-fatality ratio was 14% and rose to 43% in the case of streptococcal toxic shock syndrome. Bacteremia without identified focus (22%) and skin/soft tissue infections (30%) were the most frequent clinical presentations. Necrotizing fasciitis was frequent in adults (18%) and uncommon in children (3%). The 3 predominant emm types were emm1, emm89, and emm28, accounting for 33%, 16%, and 10% of GAS isolates, respectively. The emm1 type was associated with fatal outcomes and was more frequent in children than in adults. Six clusters of cases were identified, with each cluster involving 2 invasive cases due to GAS strains which shared identical GAS emm sequence types. Four clusters of cases involved eight postpartum infections, one family cluster involved a mother and child, and one cluster involved two patients in a nursing home. Invasive GAS infection is one of the most severe bacterial diseases in France, particularly in persons aged ≥ 50 years or when associated with toxic shock syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21976764      PMCID: PMC3232948          DOI: 10.1128/JCM.00070-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Clonal spread of emm type 28 isolates of Streptococcus pyogenes that are multiresistant to antibiotics.

Authors:  Liliana Mihaila-Amrouche; Anne Bouvet; Julien Loubinoux
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci.

Authors:  B Beall; R Facklam; T Thompson
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

3.  Comparison of invasive (septicemic) and non invasive strains of group A streptococci isolated during a one-year national survey in France. The Groupe d'Enquête 1995 sur les Infections Streptococciques.

Authors:  E Varon; H Havlickova; C Pitman; A Sarr; H Müller-Alouf; S Coignard; P Kriz; A Bouvet
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

4.  Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections.

Authors: 
Journal:  JAMA       Date:  1993-01-20       Impact factor: 56.272

5.  A family outbreak due to an emm-type 11 multiresistant strain of Streptococcus pyogenes.

Authors:  C Martinaud; A Doloy; B Graffin; T Gaillard; R Poyet; S Mallet; F Carsuzaa; P Brisou; A Bouvet
Journal:  Clin Microbiol Infect       Date:  2009-06-06       Impact factor: 8.067

6.  Risk for severe group A streptococcal disease among patients' household contacts.

Authors:  Katherine A Robinson; Gretchen Rothrock; Quyen Phan; Brenda Sayler; Karen Stefonek; Chris Van Beneden; Orin S Levine
Journal:  Emerg Infect Dis       Date:  2003-04       Impact factor: 6.883

7.  Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group.

Authors:  H D Davies; A McGeer; B Schwartz; K Green; D Cann; A E Simor; D E Low
Journal:  N Engl J Med       Date:  1996-08-22       Impact factor: 91.245

8.  Epidemiological features of invasive and noninvasive group A streptococcal disease in the Netherlands, 1992-1996.

Authors:  B Vlaminckx; W van Pelt; L Schouls; A van Silfhout; C Elzenaar; E Mascini; J Verhoef; J Schellekens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-26       Impact factor: 3.267

9.  Effect of prevention measures on incidence of human listeriosis, France, 1987-1997.

Authors:  V Goulet; H de Valk; O Pierre; F Stainer; J Rocourt; V Vaillant; C Jacquet; J C Desenclos
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Invasive group A streptococcal infection in high school football players, New York City, 2003.

Authors:  Susan E Manning; Elsie Lee; Maribeth Bambino; Joel Ackelsberg; Don Weiss; Chiminyan Sathyakumar; John Kornblum; Oxiris Barbot; Dwight Johnson; Edward L Kaplan; Marcelle Layton
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

View more
  25 in total

1.  Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002-2010.

Authors:  Chris Stockmann; Krow Ampofo; Adam L Hersh; Anne J Blaschke; Brian A Kendall; Kent Korgenski; Judy Daly; Harry R Hill; Carrie L Byington; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2012-04-24       Impact factor: 9.079

2.  Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012.

Authors:  George E Nelson; Tracy Pondo; Karrie-Ann Toews; Monica M Farley; Mary Lou Lindegren; Ruth Lynfield; Deborah Aragon; Shelley M Zansky; James P Watt; Paul R Cieslak; Kathy Angeles; Lee H Harrison; Susan Petit; Bernard Beall; Chris A Van Beneden
Journal:  Clin Infect Dis       Date:  2016-04-22       Impact factor: 9.079

Review 3.  Current insights in invasive group A streptococcal infections in pediatrics.

Authors:  Anne Filleron; Eric Jeziorski; Anne-Laure Michon; Michel Rodière; Hélène Marchandin
Journal:  Eur J Pediatr       Date:  2012-02-25       Impact factor: 3.183

4.  Molecular epidemiology of sil locus in clinical Streptococcus pyogenes strains.

Authors:  Céline Plainvert; Márcia Dinis; Miriam Ravins; Emanuel Hanski; Gérald Touak; Nicolas Dmytruk; Agnès Fouet; Claire Poyart
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

5.  An extracellular bacterial pathogen modulates host metabolism to regulate its own sensing and proliferation.

Authors:  Moshe Baruch; Ilia Belotserkovsky; Baruch B Hertzog; Miriam Ravins; Eran Dov; Kevin S McIver; Yoann S Le Breton; Yiting Zhou; Catherine Youting Cheng; Catherine Youting Chen; Emanuel Hanski
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

6.  Epidemiology and molecular characterization of macrolide-resistant Streptococcus pyogenes in Taiwan.

Authors:  Chia-Ying Huang; Jui-Fen Lai; I-Wen Huang; Pei-Chen Chen; Hui-Ying Wang; Yih-Ru Shiau; Ya-Wen Cheng; Li-Yun Hsieh; Shan-Chwen Chang; Tsai-Ling Yang Lauderdale
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

7.  Group A Streptococcus endometritis following medical abortion.

Authors:  Nicolas Gendron; Caroline Joubrel; Sophie Nedellec; Jennifer Campagna; Aubert Agostini; Florence Doucet-Populaire; Anne Casetta; Josette Raymond; Claire Poyart; Solen Kernéis
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948

8.  Gene fitness landscape of group A streptococcus during necrotizing myositis.

Authors:  Luchang Zhu; Randall J Olsen; Stephen B Beres; Jesus M Eraso; Matthew Ojeda Saavedra; Samantha L Kubiak; Concepcion C Cantu; Leslie Jenkins; Amelia R L Charbonneau; Andrew S Waller; James M Musser
Journal:  J Clin Invest       Date:  2019-01-22       Impact factor: 14.808

9.  The Mobile Genetic Element RD2 Affects Colonization Potential of Different GAS Serotypes.

Authors:  Laura C Cook
Journal:  Infect Immun       Date:  2021-07-15       Impact factor: 3.441

Review 10.  Streptococcus pyogenes and re-emergence of scarlet fever as a public health problem.

Authors:  Samson Sy Wong; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2012-07-11       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.